Ratings Tri Chemical Laboratories Inc.

Equities

4369

JP3636000006

Market Closed - Japan Exchange Other stock markets 07:00:00 10/05/2024 BST			5-day change	1st Jan Change
4,360 ^JPY	-0.68%		+1.16%	+20.78%

03-20	Tri Chemical's Attributable Profit Nearly Halves in Fiscal Year Ended January	MT
03-15	Tri Chemical Laboratories Inc. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending January 31, 2025	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

With an expected P/E ratio at 33.97 and 24.09 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Specialty Chemicals

	1st Jan change	Capi.	ESG Refinitiv
TRI CHEMICAL LABORATORIES INC.	+20.78%	917M	-
ECOLAB INC.	+17.73%	66.7B	A-
SIKA AG	+1.61%	48.83B	A-
GIVAUDAN SA	+16.33%	41.51B	B+
FUJIFILM HOLDINGS CORPORATION	+18.68%	26.72B	A-
EMS-CHEMIE HOLDING AG	+12.78%	19.58B	C+
POSCO FUTURE M CO., LTD.	-21.87%	16.02B	A-
ALBEMARLE CORPORATION	-10.29%	15.7B	C+
SYMRISE AG	+2.32%	15.58B	B+
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.	-22.30%	13.8B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes